SG145685A1 - Matrix metalloproteinase inhibitors - Google Patents
Matrix metalloproteinase inhibitorsInfo
- Publication number
- SG145685A1 SG145685A1 SG200805432-2A SG2008054322A SG145685A1 SG 145685 A1 SG145685 A1 SG 145685A1 SG 2008054322 A SG2008054322 A SG 2008054322A SG 145685 A1 SG145685 A1 SG 145685A1
- Authority
- SG
- Singapore
- Prior art keywords
- matrix metalloproteinase
- metalloproteinase inhibitors
- inhibitors
- matrix
- alloproteinase
- Prior art date
Links
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title abstract 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Soft Magnetic Materials (AREA)
- Lubricants (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321538.1A GB0321538D0 (en) | 2003-09-13 | 2003-09-13 | Therapeutically useful compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG145685A1 true SG145685A1 (en) | 2008-09-29 |
Family
ID=29227079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200805432-2A SG145685A1 (en) | 2003-09-13 | 2004-09-10 | Matrix metalloproteinase inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7601729B2 (enExample) |
| EP (3) | EP2042488B1 (enExample) |
| JP (3) | JP2007505081A (enExample) |
| KR (3) | KR20120007566A (enExample) |
| CN (1) | CN1849306B (enExample) |
| AT (2) | ATE502922T1 (enExample) |
| AU (1) | AU2004272280C1 (enExample) |
| BR (1) | BRPI0413791A (enExample) |
| CA (1) | CA2538315C (enExample) |
| CY (1) | CY1109400T1 (enExample) |
| DE (2) | DE602004031991D1 (enExample) |
| DK (1) | DK1663970T3 (enExample) |
| ES (2) | ES2314436T3 (enExample) |
| GB (1) | GB0321538D0 (enExample) |
| HR (1) | HRP20080668T3 (enExample) |
| IL (1) | IL173305A (enExample) |
| IS (2) | IS2622B (enExample) |
| MA (1) | MA28039A1 (enExample) |
| MX (1) | MXPA06002458A (enExample) |
| NO (1) | NO20060540L (enExample) |
| NZ (2) | NZ573479A (enExample) |
| PL (1) | PL1663970T3 (enExample) |
| PT (1) | PT1663970E (enExample) |
| RU (2) | RU2370488C2 (enExample) |
| SG (1) | SG145685A1 (enExample) |
| SI (1) | SI1663970T1 (enExample) |
| WO (1) | WO2005026120A1 (enExample) |
| ZA (1) | ZA200602070B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| PL1856063T3 (pl) * | 2005-02-22 | 2012-07-31 | Sun Pharmaceutical Ind Ltd | Pochodne kwasu 5-fenylopentantowego jako inhibitory metaloproteinazy macierzy do leczenia astmy i innych chorób |
| AU2013200728B2 (en) * | 2006-08-22 | 2014-12-18 | Sun Pharmaceutical Industries Limited | Matrix metalloproteinase inhibitors |
| KR101467590B1 (ko) * | 2006-08-22 | 2014-12-01 | 랜박시 래보러터리스 리미티드 | 매트릭스 메탈로프로테나제 저해제 |
| CN102015606B (zh) | 2007-06-08 | 2015-02-04 | 满康德股份有限公司 | IRE-1α抑制剂 |
| FR2949463B1 (fr) * | 2009-08-26 | 2011-09-16 | Commissariat Energie Atomique | Inhibiteurs de mmp |
| JP2013537533A (ja) | 2010-07-30 | 2013-10-03 | ランバクシー ラボラトリーズ リミテッド | マトリックスメタロプロテイナーゼ阻害剤 |
| EA201390404A1 (ru) | 2010-09-24 | 2013-09-30 | Ранбакси Лабораториз Лимитед | Ингибиторы матричной металлопротеиназы |
| WO2014083229A1 (es) | 2012-11-28 | 2014-06-05 | Administración General De La Comunidad Autónoma De Euskadi | Uso de inhibidores de metaloproteasas en el tratamiento de enfermedades hepáticas poliquísticas |
| RU2743424C2 (ru) | 2016-02-12 | 2021-02-18 | Астеллас Фарма Инк. | Производные тетрагидроизохинолина |
| JP7143334B2 (ja) * | 2017-06-13 | 2022-09-28 | エシコン エルエルシー | 治癒を制御させる手術用ステープラ |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4102024A1 (de) * | 1991-01-24 | 1992-07-30 | Thomae Gmbh Dr K | Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| AU2199195A (en) * | 1994-04-28 | 1995-11-29 | Uniroyal Chemical Company, Inc. | Fungicidal azole derivatives |
| EP0865431A2 (en) * | 1995-12-06 | 1998-09-23 | Astra Pharmaceuticals Limited | Compounds |
| IL120669A (en) | 1996-04-19 | 2001-04-30 | Akzo Nobel Nv | Benzoheterocyclic benzylamine derivatives and pharmaceutical compositions containing them |
| HRP970246B1 (en) * | 1996-05-15 | 2002-04-30 | Bayer Ag | Substituted oxobutric acids as matrix metalloprotease inhibitors |
| US6242616B1 (en) | 1996-12-03 | 2001-06-05 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| US20050065353A1 (en) | 1996-12-03 | 2005-03-24 | Smith Amos B. | Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof |
| US6096904A (en) | 1996-12-03 | 2000-08-01 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| US6870058B2 (en) | 1996-12-03 | 2005-03-22 | The Trustees Of The University Of Pennsylvania | Compounds which mimic the chemical and biological properties of discodermolide |
| US5789605A (en) | 1996-12-03 | 1998-08-04 | Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof |
| US5804581A (en) * | 1997-05-15 | 1998-09-08 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted phenalkyl compounds |
| US6608052B2 (en) * | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| WO2002083642A1 (en) * | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| AU2003261319A1 (en) * | 2002-08-01 | 2004-02-23 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
| JP2006506446A (ja) * | 2002-11-19 | 2006-02-23 | ガルデルマ・リサーチ・アンド・デヴェロップメント・エス・エヌ・セ | ＰＰＡＲ−γ型レセプターを活性化する新規二芳香族化合物、および化粧品組成物または薬剤組成物におけるその使用 |
| GB0312654D0 (en) * | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0314488D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| PL1856063T3 (pl) | 2005-02-22 | 2012-07-31 | Sun Pharmaceutical Ind Ltd | Pochodne kwasu 5-fenylopentantowego jako inhibitory metaloproteinazy macierzy do leczenia astmy i innych chorób |
| KR101467590B1 (ko) | 2006-08-22 | 2014-12-01 | 랜박시 래보러터리스 리미티드 | 매트릭스 메탈로프로테나제 저해제 |
-
2003
- 2003-09-13 GB GBGB0321538.1A patent/GB0321538D0/en not_active Ceased
-
2004
- 2004-09-10 US US10/571,443 patent/US7601729B2/en not_active Expired - Fee Related
- 2004-09-10 EP EP08163972A patent/EP2042488B1/en not_active Expired - Lifetime
- 2004-09-10 BR BRPI0413791-4A patent/BRPI0413791A/pt not_active IP Right Cessation
- 2004-09-10 SI SI200431008T patent/SI1663970T1/sl unknown
- 2004-09-10 HR HR20080668T patent/HRP20080668T3/xx unknown
- 2004-09-10 SG SG200805432-2A patent/SG145685A1/en unknown
- 2004-09-10 WO PCT/EP2004/010319 patent/WO2005026120A1/en not_active Ceased
- 2004-09-10 MX MXPA06002458A patent/MXPA06002458A/es active IP Right Grant
- 2004-09-10 RU RU2006106850/04A patent/RU2370488C2/ru not_active IP Right Cessation
- 2004-09-10 KR KR1020127000264A patent/KR20120007566A/ko not_active Ceased
- 2004-09-10 PT PT04765231T patent/PT1663970E/pt unknown
- 2004-09-10 ES ES04765231T patent/ES2314436T3/es not_active Expired - Lifetime
- 2004-09-10 AT AT08163972T patent/ATE502922T1/de not_active IP Right Cessation
- 2004-09-10 JP JP2006525794A patent/JP2007505081A/ja active Pending
- 2004-09-10 KR KR1020067005114A patent/KR20060120648A/ko not_active Ceased
- 2004-09-10 CN CN200480026229.7A patent/CN1849306B/zh not_active Expired - Fee Related
- 2004-09-10 ES ES08163972T patent/ES2362954T3/es not_active Expired - Lifetime
- 2004-09-10 CA CA2538315A patent/CA2538315C/en not_active Expired - Fee Related
- 2004-09-10 DK DK04765231T patent/DK1663970T3/da active
- 2004-09-10 NZ NZ573479A patent/NZ573479A/en not_active IP Right Cessation
- 2004-09-10 DE DE602004031991T patent/DE602004031991D1/de not_active Expired - Lifetime
- 2004-09-10 DE DE602004017622T patent/DE602004017622D1/de not_active Expired - Lifetime
- 2004-09-10 AT AT04765231T patent/ATE413384T1/de active
- 2004-09-10 NZ NZ545211A patent/NZ545211A/en not_active IP Right Cessation
- 2004-09-10 EP EP10176905A patent/EP2295408A1/en not_active Withdrawn
- 2004-09-10 PL PL04765231T patent/PL1663970T3/pl unknown
- 2004-09-10 KR KR1020137014317A patent/KR20130079628A/ko not_active Ceased
- 2004-09-10 EP EP04765231A patent/EP1663970B1/en not_active Expired - Lifetime
- 2004-09-10 AU AU2004272280A patent/AU2004272280C1/en not_active Ceased
-
2006
- 2006-01-23 IL IL173305A patent/IL173305A/en not_active IP Right Cessation
- 2006-01-26 IS IS8268A patent/IS2622B/is unknown
- 2006-02-02 NO NO20060540A patent/NO20060540L/no not_active Application Discontinuation
- 2006-03-10 ZA ZA200602070A patent/ZA200602070B/en unknown
- 2006-03-14 MA MA28873A patent/MA28039A1/fr unknown
-
2008
- 2008-11-07 US US12/266,767 patent/US8263602B2/en not_active Expired - Fee Related
- 2008-11-26 RU RU2008146479/04A patent/RU2008146479A/ru not_active Application Discontinuation
-
2009
- 2009-01-27 CY CY20091100090T patent/CY1109400T1/el unknown
- 2009-08-19 IS IS8843A patent/IS8843A/is unknown
- 2009-09-01 US US12/551,892 patent/US8343986B2/en not_active Expired - Fee Related
-
2011
- 2011-06-14 JP JP2011132261A patent/JP2011231118A/ja not_active Withdrawn
-
2012
- 2012-01-25 JP JP2012012663A patent/JP2012107031A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG145694A1 (en) | Novel compounds | |
| EP1361873A4 (en) | Matrix metalloproteinase INHIBITORS | |
| EG25482A (en) | Inhibitors | |
| IN2014CN03629A (enExample) | ||
| EP1499336A4 (en) | PROTEASE INHIBITORS | |
| EP1663281A4 (en) | POLY-PEGYLATED PROTEASE INHIBITORS | |
| AU2003248122A8 (en) | Sodium channel inhibitor | |
| AU2003249531A1 (en) | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | |
| AU2003249477A1 (en) | Heterobicylcic metalloproteinase inhibitors | |
| EP1663279A4 (en) | MODIFIED PROTEASE INHIBITORS | |
| EP1704142A4 (en) | PROTEASE INHIBITORS | |
| SG145685A1 (en) | Matrix metalloproteinase inhibitors | |
| AU2003299901A8 (en) | Thrombin inhibitors | |
| ZA200409691B (en) | Heterotricyclyl 6-alkylidene-penems as ß-lactamase inhibitors | |
| AU2003269984A8 (en) | Protease inhibitors | |
| EP1531857A4 (en) | Metalloproteinase inhibitors | |
| PL375304A1 (en) | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | |
| AU2003263738A8 (en) | Protease inhibitors | |
| AU2003304496A8 (en) | Protease inhibitors | |
| AU2003227952A8 (en) | Metalloproteinase inhibitors | |
| AU2003233642A8 (en) | Protease inhibitors | |
| AU2003265240A8 (en) | Protease inhibitors | |
| AU2003269878A8 (en) | Protease inhibitors | |
| GB0319917D0 (en) | Metalloproteinase inhibitors | |
| GB0328632D0 (en) | Metalloproteinase inhibitors |